Eagle: ‘No Room, No Reason’ For A Generics Business, As Vasopressin Pulled
US-Based Firm Will Not Rule Out Returning To Market – ‘If Things Change’
Executive Summary
In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.
You may also be interested in...
Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico
On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.
US Supreme Court Reignites Claims Government Overcharged Millions For Generics
In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.
Sandoz Reveals New Headquarters Post Spin, Mid-2024 Date Outlined
Tracing its roots back to Basel in the late nineteenth century, Sandoz has confirmed the location of its new planned permanent headquarters post-spin.